Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927)

Sherry Shen, Joseph M. Unger, Katherine D. Crew, Cathee Till, Heather Greenlee, Julie Gralow, Shaker R. Dakhil, Lori M. Minasian, James L Wade, Michael J. Fisch, N. Lynn Henry, Dawn L. Hershman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Purpose: Although aromatase inhibitors (AIs) prolong survival in post-menopausal breast cancer (BC) patients, AI-associated arthralgia can lead to discontinuation. Obese patients have higher rates of AI arthralgia than non-obese patients, but treatment options are limited. Omega-3 fatty acid (O3-FA) treatment for AI arthralgia has produced mixed results. Methods: We performed an exploratory analysis of SWOG S0927, a multicenter randomized placebo-controlled trial of O3-FA use for AI arthralgia. Post-menopausal women with stage I–III BC taking an AI were randomized to 24 weeks of O3-FAs or placebo. Brief Pain Inventory (BPI) questionnaires and fasting serum were collected at baseline, 12, and 24 weeks. The BPI assessment included worst pain, average pain, and pain interference scores (range 0–10). Results: Among the 249 participants, 139 had BMI < 30 kg/m 2 (56%) and 110 had BMI ≥ 30 kg/m 2 (44%). Among obese patients, O3-FA use was associated with significantly lower BPI worst pain scores at 24 weeks compared with placebo (4.36 vs. 5.70, p = 0.02), whereas among non-obese patients, there was no significant difference in scores between treatment arms (5.27 vs. 4.58, p = 0.28; interaction p = 0.05). Similarly, O3-FA use was associated with lower BPI average pain and pain interference scores at 24 weeks compared with placebo among obese patients, but no significant difference between treatment arms in non-obese patients (interaction p = 0.005 and p = 0.01, respectively). Conclusions: In obese BC patients, O3-FA use was associated with significantly reduced AI arthralgia compared to placebo.

Original languageEnglish (US)
Pages (from-to)603-610
Number of pages8
JournalBreast Cancer Research and Treatment
Volume172
Issue number3
DOIs
StatePublished - Dec 1 2018

Keywords

  • Aromatase inhibitor
  • Arthralgia
  • Breast cancer
  • Obesity
  • Omega-3 fatty acids

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927)'. Together they form a unique fingerprint.

Cite this